#Italy #Drug Discovery #Rome #Functional Genomics #IRBM

IRBM's Functional Genomics Platform: A Game Changer in Drug Discovery

In a groundbreaking announcement, IRBM, a leading Contract Research Organization (CRO), has unveiled an advanced Functional Genomics Platform aimed at revolutionizing the early stages of drug discovery. This initiative signals a pivotal moment in preclinical research, offering innovative approaches to genetic target identification, validation, and the creation of disease-relevant cellular models.

The platform integrates a range of cutting-edge techniques, including CRISPR-based methodologies and high-throughput screening capabilities, ultimately enhancing target validation processes. It will enable researchers to systematically map functional domains within genes, applying CRISPR tiling among other state-of-the-art editing techniques. By implementing base and prime editing, scientists can achieve precise nucleotide modifications, a factor crucial for developing robust disease models and validating targets effectively.

Dr. Sara Tomaselli, Head of Functional Genomics at IRBM, emphasizes the complexity of validating genuine targets for drug development. She notes, "With this in-house platform, we're strengthening our ability to systematically evaluate gene function, de-risk early discovery, and support our partners in making well-informed decisions."

The Functional Genomics Platform boasts both genome-wide and targeted CRISPR libraries designed to facilitate knockout (CRISPR KO), inhibition (CRISPRi), and activation (CRISPRa). This capability allows for in-depth exploration of gene functions and their associated pathways, enabling researchers to gain critical insights that can transform the drug discovery landscape.

Concurrently, IRBM's expertise in cell engineering—spanning patient-relevant models and induced pluripotent stem cell (iPSC)-derived systems—supports comprehensive disease modeling in various fields, including oncology, neurodegeneration, and rare diseases. To enhance functional characterization further, the integration of multi-omics technologies such as single-cell transcriptomics and proteomics offers researchers more profound insights into drug targets.

The launch of this platform is part of IRBM's broader vision of creating a fully integrated drug discovery ecosystem. By bridging the gap between genetic insights and practical preclinical models, the company is paving the way for innovative drug development strategies. Dr. Carlo Toniatti, Chief Scientific Officer at IRBM, states, "We take a careful, methodical approach to functional genomics—one that integrates well with the complexities of drug discovery. Our goal is to help our partners uncover high-quality targets and generate data that can guide and inform decision making throughout the entire drug discovery process."

In light of these advancements, IRBM welcomes biotech startups, pharmaceutical companies, and venture-backed teams to leverage its functional genomics expertise without needing extensive in-house infrastructure. Offering customized solutions ranging from genetic screening and engineered cell models to mechanistic studies, IRBM stands ready to provide practical and scientifically rigorous support to crucial points in drug discovery.

To explore collaboration opportunities or learn more about the Functional Genomics Platform, visit IRBM's official website. With its commitment to scientific precision and transparency, IRBM positions itself as a trusted partner in advancing therapeutic development.

About IRBM

IRBM is a dedicated CRO that focuses on early-stage drug discovery. Renowned for delivering preclinical candidates across various therapeutic areas, including oncology, neurodegeneration, and infectious diseases, IRBM collaborates with biotech and pharmaceutical innovators to drive the development of groundbreaking therapies with scientific rigor.